Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 17/20 | 0.48 |
| ▸ | CCNE1 | P24864 | 14/20 | 0.48 |
| ▸ | FLT3 | P36888 | 14/20 | 0.48 |
| ▸ | KIT | P10721 | 1/20 | 0.46 |
| ▸ | TYK2 | P29597 | 1/20 | 0.43 |
| ▸ | MAPKAPK2 | P49137 | 2/20 | 0.40 |
| ▸ | GSK3B | P49841 | 2/20 | 0.39 |
| ▸ | CDK1 | P06493 | 1/20 | 0.39 |
| ▸ | PIM1 | P11309 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13213956 | 0.84 | CCNE1 (0.66) | CDK2CCNE1FLT3KITTYK2 | |
| SCHEMBL103715 | 0.84 | CCNE1 (0.66) | CDK2CCNE1FLT3KITTYK2 | |
| SCHEMBL3024175 | 0.73 | CCNE1 (0.56) | CDK2CCNE1FLT3KITTYK2 | |
| SCHEMBL3024179 | 0.73 | CCNE1 (0.56) | CDK2CCNE1FLT3KITTYK2 | |
| SCHEMBL13234486 | 0.73 | CCNE1 (0.59) | CDK2CCNE1FLT3KITTYK2 | |
| SCHEMBL12012864 | 0.72 | CDK2 (0.68) | CDK2CCNE1FLT3KITTYK2 | |
| SCHEMBL12013113 | 0.72 | CDK2 (0.68) | CDK2CCNE1FLT3KITTYK2 | |
| SCHEMBL3022986 | 0.72 | TYK2 (0.78) | CDK2CCNE1FLT3KITTYK2 | |
| SCHEMBL3022983 | 0.72 | TYK2 (0.78) | CDK2CCNE1FLT3KITTYK2 | |
| SCHEMBL17920868 | 0.72 | CCNE1 (0.72) | CDK2CCNE1FLT3KIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120059162-A1 | FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION | ONCOTHERAPY SCIENCE, INC. (JP) | 2012-03-08 | — | — | US | disclosed |
| US-20120059162-A1 | FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION | ONCOTHERAPY SCIENCE, INC. (JP) | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059162-A1 | FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION | NR0B1, GRK7, NR5A2 | CDK2 787/4885CCNE1 1554/4885FLT3 1514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.